The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global human growth hormone market exhibited strong growth during 2015-2020. HGH is a peptide hormone that is produced by the pituitary gland to stimulate growth in children and adults. The hormone primarily regulates growth, regeneration, repair, reproduction and metabolism of the cells, thus contributing to the overall development of the body. It also regulates body fluids, fat metabolism and bone and muscle growth. The deficiency of HGH can increase the risk of diseases and fat accumulation, whereas higher levels can cause gigantism in children and acromegaly, muscle-wasting disease and short bowel syndrome in adults.
The increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. Furthermore, increasing health consciousness among the masses and growing awareness regarding the preventive measures against endocrine disorders, are providing a boost to the market growth. Various disorders, such as Prader-Willi syndrome (PWS) and idiopathic short stature (ISS), are caused by the deficiency of growth hormones in the body that can be treated using medically synthesized HGH. Other factors, including a rising utilization of HGH as performance enhancers by bodybuilders, along with the development of recombinant human growth hormone (rHGH), are projected to drive the market further. Looking forward, IMARC Group expects the global human growth hormone market to grow at a CAGR of 8.2% during 2021-2026.
Breakup by Application:
Breakup by Distribution Channel:
Breakup by Route of Administration:
Breakup by Region:
The competitive landscape of the industry has also been examined with some of the key players being Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc., Sandoz, etc.
|Base Year of the Analysis||2020|
|Segment Coverage||Application, Distribution Channel, Route of Administration, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Eli Lilly and Company, EMD Serono Inc., F. Hoffmann-La Roche AG, Ferring B.V., Genentech Inc., Ipsen, Merck KGaA, Novartis AG, Novo Nordisk, Pfizer Inc. and Sandoz|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2299
Five User License: US$ 3399
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at